Taiwan's non-profit Development Center for Biotechnology (DCB) announced Monday that it has synthesized favilavir, an experimental medication being used in other countries as an investigational therapy to combat the COVID-19 coronavirus.
(Full text of the story is now in CNA English news archive. To view the full story, you will need to be a subscribed member of the CNA archive. To subscribe, please read here.)
Latest
- Business
CPC keeps residential, industrial gas prices steady; utility rates to drop
06/30/2026 08:32 PM - Society
Taiwan's new workplace bullying rules: What to know
06/30/2026 08:31 PM - Society
Taiwan to add rotavirus vaccine to free immunization program in 2027
06/30/2026 08:13 PM - Business
Taiwan's 2025 domestic production of export orders hits record 52.9%
06/30/2026 07:50 PM - Society
Taipei Metro to accept credit cards and mobile pay starting July 1
06/30/2026 06:20 PM